Navigation Links
Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
Date:2/7/2008

SEATTLE, Feb. 7 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that Mitchell H. Gold, M.D., chairman and chief executive officer of Dendreon, will present a company update at the 10th Annual BIO CEO & Investor Conference in New York City, on Wednesday, February 13, 2008 at 1:15 p.m. ET.

A live audio webcast of the presentation will be accessible through the Investor Relations section of the Dendreon website, http://www.dendreon.com. If you are unable to listen to the live webcast, it will be archived on the site following the presentation. To access the replay, go to the Investor Relations section of the website.

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Active cellular immunotherapy holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
2. Dendreon Reports Third Quarter 2007 Financial Results
3. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
4. Dendreon Secures $130 Million Committed Equity Financing Facility
5. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. VIRxSYS Announces Interim Results from VRX496 Gene Therapy Phase II Trial
8. Exelixis Announces February 12 Webcast of Presentation at the 10th Annual BIO CEO and Investor Conference
9. Global Probiotics Council Announces Young Investigator Grant for Probiotics Research to Fund the Next Generation of Gut Microbiota Research
10. Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Second Quarter Results of Fiscal Year 2008
11. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... ... August 04, 2015 , ... On August 4, 2015, the White House will ... from across the United States to talk about their experiences with innovation and present ... to be among the attendees. , One of the day’s aims is to grow ...
(Date:8/3/2015)... 3, 2015 At the 11th ... waved the shortfall of Jude Liversage,s ... for the first time.      (Photo: ... ) The Selective Dorsal Rhizotomy (SDR) ... to carry out his wish to kick a ball ...
(Date:8/3/2015)...  Aethlon Medical, Inc. (Nasdaq: AEMD ), the ... diseases, today announced that it will host its First ... Thursday, August 13, 2015 at 4:30 p.m. Eastern Time. ... release of fiscal 2016 first quarter results.  A recorded ... hours after the call at the Investor Relations portion ...
(Date:8/3/2015)... ... August 03, 2015 , ... Sterlitech ... to its comprehensive line of analytical laboratory equipment. With optimized features, such as ... provide a chemically resistant and maintenance-free solution for a broad range of vacuum ...
Breaking Biology Technology:White House Invites uBiome CEO Jessica Richman to First-Ever Startup Demo Day 2Cerebral Palsy Operation by The Portland Hospital Allows a Boy to Stand Properly for the First Time 2Cerebral Palsy Operation by The Portland Hospital Allows a Boy to Stand Properly for the First Time 3Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015 2Sterlitech Launches New Line of Vacuum Pumps 2
... A ... Biology are Natural Partners in the Fight Against Disorder. , ... (PRWEB) November 3, 2009 -- MyPhield Technology ... naturally relieves osteoarthritis without causing unwanted side-effects, is now available online at www.ReliefForLife.ca ...
... 3 ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), ... 30, 2009. ISTA reported net revenue of $32.0 million ... increase over net revenue for the three months ended September ... months ended September 30, 2009 is $1.2 million associated with ...
... SAN MARCOS, Texas, Nov. 3 Texas State University ... agreement today that will permit University Researchers to continue ... potential and effectiveness of ALKA-V6, a compound which has ... the HIV virus in laboratory experiments. , The research ...
Cached Biology Technology:New Technology Now Available In Canada For Osteoarthritis 2ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results 2ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results 3ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results 4ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results 5ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results 6ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results 7ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results 8ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results 9Texas State University Prepares for Phase 2 Research on the Potential New Cancer and HIV Fighting ALKA-V6 Compound 2Texas State University Prepares for Phase 2 Research on the Potential New Cancer and HIV Fighting ALKA-V6 Compound 3
(Date:7/31/2015)... SHENZHEN, China , 31 de julho de 2015 ... Genômica (ICG-10, www.icg-10.org ) será realizada pela BGI de ... China . A conferência está ... inauguração em 2006, a ICG se tornou uma das ... e um dos encontros científicos mais dinâmicos, entusiastas e ...
(Date:7/31/2015)... -- The 10 th International Conference on Genomics (ICG-10, ... 2015, in Shenzhen , China ... th anniversary this year. Since its inauguration in 2006, ... meetings in the ,omics, fields, and is one of the ... ICG-10 focuses on recent breakthroughs and advances in ,omics, research ...
(Date:7/23/2015)... July 23, 2015 Research and Markets ... the "Global Outlook of the Biometrics Industry ... The global biometrics market is likely ... commercial applications owing to the uptake of multiple ... transformation that enhances the growth of biometrics in ...
Breaking Biology News(10 mins):A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3The 10th International Conference on Genomics (ICG-10) to Open in October 2Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3
... an experimental vaccine targeting West Nile virus (WNV) opened ... Center in Bethesda, MD. The vaccine, which will be ... for human clinical studies by researchers at the National ... Center (VRC), and Vical Inc., San Diego, based on ...
... of New York University, in collaboration with Memorial Sloan ... change in shape in a carcinogen-damaged DNA site--in tumor ... in cigarette smoke. This finding may open new horizons ... The findings appear as the cover story in the ...
... favor, 34 against and 37 abstaining, with 36 absent, ... UN Member States to ban all forms of human ... human dignity and the protection of human life. , ... banning therapeutic cloning. The Declaration, negotiated by a Working ...
Cached Biology News:NIAID begins clinical trial of West Nile virus vaccine 2NIAID begins clinical trial of West Nile virus vaccine 3NYU and MSKCC research provides model for understanding chemically induced cancer initiation 2UN votes to ban human cloning 2
Rat whole blood (Sprague-Dawley, averaging 7-8 weeks of age, either sex) is collected at the time of slaughter and refrigerated within 6 hours, and processed and frozen within 24 hours. The serum is ...
... mutS and ES1301 mutS are mismatch repair ... these strains prevents repair of the newly ... mutation efficiencies and making them helpful in ... Sites II Mutagenesis Systems. Both ES1301 and ...
propidium iodide *1.0 mg/mL solution in water*...
SHEEP ANTI ECHIS OCCELATUS (VENOM)...
Biology Products: